^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
VIP236
i
Other names: VIP236, VIP 236, VIP-236
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Vincerx
Drug class:
Topoisomerase I inhibitor, αvβ3 integrin antagonist
Related drugs:
3d
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer (clinicaltrials.gov)
P1, N=29, Completed, Vincerx Pharma, Inc. | Recruiting --> Completed | Trial primary completion date: Mar 2024 --> Oct 2024
Trial completion • Trial primary completion date • Metastases
|
VIP236
1year
Discovery of VIP236, an αvβ3-Targeted Small-Molecule-Drug Conjugate with Neutrophil Elastase-Mediated Activation of 7-Ethyl Camptothecin Payload for Treatment of Solid Tumors. (PubMed, Cancers (Basel))
Treatment with VIP236 resulted in long-lasting tumor regression in subcutaneous patient-derived xenograft (PDX) models from patients with non-small-cell lung, colon, and renal cancer as well as in two orthotopic metastatic triple-negative breast cancer PDX models. In these models, a significant reduction of brain and lung metastases also was observed.
Journal
|
VIP236
over1year
VIP236: A small molecule drug conjugate with an optimized camptothecin payload has significant activity in patient-derived and metastatic cancer models (AACR 2023)
In summary, VIP236 monotherapy efficacy in NSCLC, gastric, TNBC, RCC, CRC, and metastatic TNBC in vivo cancer models provides a rationale for clinical investigation in advanced metastatic solid tumors. In gastric cancer, VIP236 showed improved efficacy compared with the approved ADC, trastuzumab deruxtecan, regardless of HER2 expression. These results warrant further evaluation in clinical trials.
Clinical • Preclinical • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
|
Enhertu (fam-trastuzumab deruxtecan-nxki) • VIP236
Share via
